Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Payables: 2019-2025

Historic Payables for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $6.9 million.

  • 4D Molecular Therapeutics' Payables rose 134.71% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 71.08%. This contributed to the annual value of $4.4 million for FY2024, which is 24.78% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Payables of $6.9 million as of Q3 2025, which was down 21.11% from $8.7 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Payables peaked at $8.7 million during Q2 2025, and registered a low of $1.3 million during Q1 2021.
  • For the 3-year period, 4D Molecular Therapeutics' Payables averaged around $4.4 million, with its median value being $4.2 million (2025).
  • Per our database at Business Quant, 4D Molecular Therapeutics' Payables tumbled by 60.14% in 2022 and then surged by 218.45% in 2023.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Payables stood at $4.8 million in 2021, then tumbled by 30.27% to $3.3 million in 2022, then grew by 5.81% to $3.5 million in 2023, then rose by 24.78% to $4.4 million in 2024, then surged by 134.71% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $8.7 million for Q2 2025, and $4.2 million during Q1 2025.